

Effect of Psychological Intervention on Fear of Cancer Recurrence: A Systematic Review and Meta-Analysis

Nina M. Tauber, MSc^{1,2}; Mia S. O'Toole, MSc, PhD¹; Andreas Dinkel, DSc^{2,3}; Jacqueline Galica, PhD^{2,4}; Gerry Humphris, PhD^{2,5}; Sophie Lebel, PhD^{2,6}; Christine Maheu, PhD^{2,7}; Gozde Ozakinci, PhD^{2,5}; Judith Prins, MSc, PhD^{2,8}; Louise Sharpe, MS, PhD^{2,9}; Allan "Ben" Smith, PhD^{2,10}; Belinda Thewes, PhD^{2,9}; Sébastien Simard, PhD^{2,11}; and Robert Zachariae, DMSc^{1,2,12}

PURPOSE Fear of cancer recurrence (FCR) is a significantly distressing problem that affects a substantial number of patients with and survivors of cancer; however, the overall efficacy of available psychological interventions on FCR remains unknown. We therefore evaluated this in the present systematic review and meta-analysis.

METHODS We searched key electronic databases to identify trials that evaluated the effect of psychological interventions on FCR among patients with and survivors of cancer. Controlled trials were subjected to meta-analysis, and the moderating influence of study characteristics on the effect were examined. Overall quality of evidence was evaluated using the GRADE system. Open trials were narratively reviewed to explore ongoing developments in the field (PROSPERO registration no.: CRD42017076514).

RESULTS A total of 23 controlled trials (21 randomized controlled trials) and nine open trials were included. Small effects (Hedges's *g*) were found both at postintervention ($g = 0.33$; 95% CI, 0.20 to 0.46; $P < .001$) and at follow-up ($g = 0.28$; 95% CI, 0.17 to 0.40; $P < .001$). Effects at postintervention of contemporary cognitive behavioral therapies (CBTs; $g = 0.42$) were larger than those of traditional CBTs ($g = 0.24$; $\beta = .22$; 95% CI, .04 to .41; $P = .018$). At follow-up, larger effects were associated with shorter time to follow-up ($\beta = -.01$; 95% CI, $-.01$ to $-.00$; $P = .027$) and group-based formats ($\beta = .18$; 95% CI, .01 to .36; $P = .041$). A GRADE evaluation indicated evidence of moderate strength for effects of psychological intervention for FCR.

CONCLUSION Psychological interventions for FCR revealed a small but robust effect at postintervention, which was largely maintained at follow-up. Larger postintervention effects were found for contemporary CBTs that were focused on processes of cognition—for example, worry, rumination, and attentional bias—rather than the content, and aimed to change the way in which the individual relates to his or her inner experiences. Future trials could investigate how to further optimize and tailor interventions to individual patients' FCR presentation.

J Clin Oncol 37:2899-2915. © 2019 by American Society of Clinical Oncology

Licensed under the Creative Commons Attribution 4.0 License

INTRODUCTION

Despite improved treatments and prognoses, many survivors of cancer face the possibility that their cancer may return. For some, uncertainty leads to high levels of fear of cancer recurrence (FCR), which is defined as the “fear, worry, or concern about cancer returning or progressing.”^{1(p424)} Individuals with active disease may fear that stable disease will progress, and survivors of cancer have been found to fear recurrence after completion of active treatment.² Such fears and worries can thus be present from the beginning of diagnosis and continue throughout treatment and the survivorship trajectory. It is common to experience some degree of FCR, and transitory or low levels of FCR may even be adaptive, alerting the patient to signs of new or recurring cancer and encouraging positive health behaviors.^{3,4} Persistent and excessive fear, however, can be highly debilitating.^{1,2,5}

FCR is among the most commonly reported concerns by survivors of cancer and often their most frequently endorsed unmet need.⁶ A comprehensive review² estimates that, across different cancers, 22% to 87% of survivors of cancer report moderate to high FCR, and 0% to 15% report high or clinical levels of FCR, although there currently is no agreed upon clinical cutoff. Furthermore, FCR seems to remain relatively stable over time.^{2,7} Associations have been reported between FCR and depression, poorer quality of life, and impaired functioning,^{4,8} and a growing body of evidence suggests that people with high FCR may both overuse health services and avoid appropriate tests to identify recurrence in a timely fashion.⁹ These results emphasize the need for effective, evidence-based treatments for FCR.

Interventions for FCR are emerging and the number of randomized controlled trials (RCTs) that have

ASSOCIATED CONTENT

Data Supplement

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on July 1, 2019 and published at jco.org on September 18, 2019; DOI <https://doi.org/10.1200/JCO.19.00572>

evaluated such interventions is expanding rapidly. A recent review¹⁰ identified five RCTs of FCR interventions that were published in 2016 and 2017 alone, and several study protocols and feasibility studies have been published during this period.¹¹⁻¹⁸ The exact number of existing psychological interventions for FCR has not been systematically identified, and little is known about their efficacy in alleviating FCR symptoms. Thus far, only one meta-analytical evaluation of the effect of mind–body interventions on FCR and cancer-related uncertainty in 19 RCTs has been published,¹⁹ which reported a small effect both at postintervention (Hedges's $g = -0.36$; $P < .001$) and at follow-up ($g = -0.31$; $P < .001$). However, this study included not only psychological interventions, but also physical interventions—for example, yoga or dance. Second, only 13 of the 19 studies included an FCR-specific measure, with the remaining studies assessing more general cancer-related uncertainty. Although cancer-related uncertainty overlaps with FCR,²⁰⁻²³ uncertainty does not necessarily pertain to the perceived risk of recurrence or progression, but can also relate to other issues that are associated with cancer diagnosis and treatment, including work-related issues or symptom management. Third, potentially important between-study differences remained unexplored in the former review,¹⁹ including the type of psychotherapeutic framework and whether the intervention specifically targeted FCR. Finally, the number of FCR interventions being developed and evaluated is rapidly expanding, and not all relevant studies were included in the former review. Taken together, attempts to synthesize the literature on psychological interventions for FCR are limited, and an up-to-date review of current developments in the field is lacking.¹

The primary objective of the current study was to conduct a systematic review and meta-analysis of the efficacy of psychological interventions for alleviating FCR among patients with and survivors of cancer as evaluated in controlled trials. We hypothesized that psychological interventions are efficacious in reducing FCR symptoms. A secondary aim was to explore the possible influence of between-study differences in psychotherapeutic framework, treatment format, intervention dose, cancer type, patient characteristics, study design, and risk of bias. Finally, to explore current developments in the field, we aimed to conduct a narrative evaluation of open trials (OTs) and noninferiority trials.

METHODS

The current study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was preregistered with PROSPERO (registration no.: CRD42017076514).²⁵

Search Strategy

We conducted keyword-based searches in PubMed, PsycINFO, Cochrane, CINAHL, and Embase databases. Keywords

related to cancer (eg, neoplasm or oncology) were combined with keywords related to intervention (eg, psychotherap* or “cognitive-behav* therap*” or “psychol* treatment”) and terms related to fear (anxiet* or worr* or fear* or concern) and recurrence (relapse or recur* or progress*). The full search string is shown in the Data Supplement. Searches were conducted for the period from the earliest time available until June 2018, together with backward searches (snowballing) of reference lists of identified articles and earlier systematic reviews and forward searches (citation tracking).

Selection Procedure and Data Extraction

English language reports published in peer-reviewed sources were included. We assessed study eligibility using the PICO approach (population, intervention, comparison, and outcome).²⁶

Population: adult patients with or survivors of cancer (age 18 years or older). Studies of children and adolescents with cancer, patients without current cancer or a cancer history, or caregivers of patients with cancer were excluded.

Intervention: any psychological intervention that consisted primarily (> 50%) of psychological methods—for example, cognitive-behavioral, psycho-educative, imagery-based, and meditative approaches. Interventions that involved physical approaches—for example, yoga or exercise—could be included in the intervention but only if they were a secondary component (< 50%). Interventions were not required to directly target FCR.

Comparison: Eligible studies were required to use a control group—for example, waitlist, treatment as usual, or attention/active control. Case studies, studies that included only two active psychological interventions and no control group (eg, noninferiority trials), and open trials that employed uncontrolled pre–post designs were excluded from the meta-analysis. OTs, however, were included in the narrative systematic review.

Outcome: pre- and postintervention data, or pre–post change score data on one or more quantitative FCR-relevant construct. FCR could be both primary and secondary outcome. Only measures that pertained to concerns about the return or progression of cancer were included. Studies that used qualitative assessments, quantitative measures at one time point only, or only measures of general anxiety or worry were excluded. Studies needed to report results as either pre–post means and standard deviation/SE in all groups, change scores in all groups, effect sizes (ESs; eg, Cohen's d or η^2), or provide other data that could be converted to an ES.

One author removed duplicates (A.B.S.) and five authors (N.M.T., J.G., A.B.S., B.T., and S.S.) took turns in pairs, each screening one third of the records and ensuring that

all records were independently evaluated by two authors. Full texts of the remaining references were evaluated and reasons for exclusion registered (Data Supplement). Disagreements were discussed with a third author (N.M.T., B.T., or S.S.) until a negotiated conclusion was reached. Data were extracted by one author (N.M.T.) and checked by another author (C.M.). Studies were coded according to a priori-specified characteristics, including study, intervention, participant characteristics, and risk of bias.

Computing ESs

Hedges's g , a variation of Cohen's d ,²⁷ correcting for possible bias as a result of small sample sizes,²⁸ was used as the standardized between-group ES. Whenever possible, ESs were computed using means and their standard deviations for preintervention, postintervention, or change scores. If unavailable, ESs were estimated on the basis of other reported statistics—for example, P values, F values, or B values. Pooled ESs were weighted by the inverse SE, taking into account the precision of each study. The N used in the calculation was the N in the final analysis. A random effects model was chosen for all analyses, with positive values indicating ESs in the hypothesized direction. If studies reported results for more than one measure per outcome, the independence of results was ensured by averaging ESs across all outcomes so that only one result per study was used for each quantitative data synthesis.

Heterogeneity

Heterogeneity was explored using Q and I^2 statistics.²⁹ Because of the generally low statistical power of heterogeneity tests, a more liberal P value of $\leq .10$ was used to determine significant heterogeneity.³⁰ The I^2 statistic is an estimate of the variance in a pooled ES that is accounted for by heterogeneity in the sample of studies and is unaffected by the number of studies (K).³¹ I^2 values of 0%, 25%, 50%, and 75% are taken to indicate no, low, moderate, and high heterogeneity, respectively.

Publication Bias

Positive and negative findings are not equally likely to be published, and publication bias is a widespread problem when reviewing available evidence.³² We evaluated publication bias using funnel plots and Egger's test.³³⁻³⁵ If results indicated possible publication bias, adjusted ESs were calculated using the Duval and Tweedie trim-and-fill method.³⁶ In the case of statistically significant results, we calculated the failsafe number^{33,37}—that is, the number of unpublished studies with null findings that would reduce the results to statistical nonsignificance ($P > .05$)—and evaluated the robustness of results by comparing the failsafe number with the suggested criterion ($5K + 10$).³⁷

Risk of Bias Assessment

We adapted the Cochrane Collaboration tool³⁸ to evaluate the risk of bias within the context of psychological intervention studies. We included the original domains of

“random sequence allocation”, “allocation concealment”, “blinding of outcome assessment”, “accounting for attrition”, and “selective reporting”. We further differentiated “other sources of bias” with three subdomains: “treatment integrity” (ie, therapist training and fidelity), “conflict of interest” (ie, the trial was conducted by the therapists and/or the original developers of the therapy), and “bias in sampling and dropout” (eg, convenience sampling and uneven dropouts in intervention and control groups). Two authors (L.S. and G.O.) performed ratings independently. Disagreements were discussed with a third author (N.T.) until a negotiated final rating was reached for each study. Before the negotiation of a final rating, independent ratings were subjected to inter-rater reliability analyses (inter-rater agreement and κ statistics).³⁹ Risk of bias scores were calculated for each study by evaluating the risk of bias for every item above as low, unclear (or not applicable), or high risk, rated as 0, 1, and 2, respectively. Associations between ESs and risk of bias scores were explored using meta-regression. Risk of bias scores were not used as weights when calculating aggregated ESs, as this is discouraged because of the risk of inducing bias.⁴⁰

Analytical Strategy

OTs and noninferiority trials were descriptively reviewed, and controlled trials (CTs) were subjected to meta-analysis to determine the pooled overall ES. Pooled ESs from baseline to post-treatment results and follow-up results were calculated separately. If multiple follow-up assessments were included, the longest follow-up assessment was chosen. Moderation analyses were performed with meta-regression on the basis of random-effects models and were estimated using the maximum likelihood method when data were available for 10 or more studies. Analyses were conducted using Comprehensive Meta-Analysis version 3 (<http://www.meta-analysis.com>).

We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system⁴¹ to rate the quality of evidence of the meta-analytic results. Quality of evidence was graded as high, moderate, low, or very low. GRADE uses a baseline rating of high for RCTs and low for non-RCTs. This rating can be downgraded or upgraded on the basis of eight assessment criteria, including risk of bias, inconsistency of results, indirectness, imprecision, publication bias, effect magnitude, dose-response gradient, and the effect of all plausible confounding factors that would reduce the effect or suggest a spurious effect when no effect is found. Ratings were conducted and negotiated by two authors (M.S.O. and R.Z.).

RESULTS

The study selection process with reasons for exclusion is described in Figure 1 and the Data Supplement. The literature search yielded 1,394 references, of which 32 independent studies were subjected to descriptive

evaluation. Of these, 23 CTs were subjected to meta-analytic evaluation.

CT Characteristics

Study characteristics are listed in Table 1. The 23 CTs included a total of 2,965 patients with a mean sample size of 129.^{42-60,62-64} Of these, 21 studies reported post-treatment data, with 16 of these reporting relevant follow-up data. Two additional studies reported long-term (follow-up) data only. Post-treatment data were analyzed for 2,163 participants. Follow-up data were obtained 29 weeks on average after intervention and were analyzed for 2,044 participants. Most studies were RCTs (K = 21), with most control groups receiving no therapist attention (K = 19). Of the eight studies with FCR as the primary target of the intervention, FCR severity was an inclusion criterion in four studies only. All but one study were conducted in Western countries, participants were predominantly white, and, in most studies, the majority of participants were women (K = 21). Breast cancer was the most frequent cancer diagnosis (K = 15) and, in the majority of studies (K = 18), participants had no evidence of disease.

The 23 CTs evaluated a total of 25 interventions. Ten interventions used a traditional cognitive behavioral therapy (CBT) framework and nine interventions were contemporary CBTs. Studies were categorized as traditional CBT when interventions adhered to traditional cognitive behavioral principles that focus not only on Beckian therapy, but also on cognitive therapy principles that rely on information processing models in which the individual is assumed to hold biases, which gives rise to dysfunctional

thoughts and beliefs.^{73,74} Contemporary CBTs were defined as interventions that were focused on the processes, rather than the content of cognition—for example, worry, rumination, attentional bias, and cognitive fusion—and aimed to change the way in which the individual related to his or her inner experiences.⁷⁵⁻⁷⁷ The remaining six interventions—other interventions—varied too much to be meaningfully grouped (eg, as psychodynamic therapy or supportive therapy). Approximately one half of interventions were group based (K = 13), with the remaining using an individual format (K = 12). In most studies, interventions were delivered face to face (K = 19). Number of sessions ranged from one to 15 (mean, 6.6). Reducing FCR was the primary aim in eight studies only.

OT Characteristics

Nine OTs were eligible for descriptive evaluation (Table 1). All studies were described as feasibility or pilot studies and had sample sizes that ranged from eight to 56 (mean, 29.1). FCR severity was the inclusion criterion in three studies. Samples included prostate, breast, ovarian, and mixed types of cancer, with participants in three studies having current cancer. Five interventions could be categorized as traditional CBTs and the remaining four as contemporary CBTs. Five interventions had a primary aim of reducing FCR. Intervention was delivered in groups in four studies, all but three interventions were delivered face to face, and the number of sessions ranged from one to 10 (mean, 5.7). Eight studies reported positive statistically significant small-to-large within-subject ESs (range: Hedges's *g* = 0.33-3.15).^{18,65-67,69,71,72} The remaining study




FIG 1. Study selection flowchart. FCR, fear of cancer recurrence.

TABLE 1. Study Characteristics

Study (country)	Cancer Type; Cancer Present (yes/no); Stage	Demographic Characteristics	Study Design; No. of Arms	FCR Measure		Intervention Type*	FCR Severity as Inclusion Criteria; FCR as Primary Outcome	Delivery Mode; No. of Sessions; Duration, Weeks (FU)†	Treatment Format; Initial No.; Analyzed No. (post, FU)
				CWS	CARS				
Controlled trials									
Cameron ⁴² (New Zealand)	Breast	Mean age, 50.7 years	CT	CWS	CARS	Contemporary CBT	No	Face to face	Group
	Yes	94.2% white	2				No	12	154
	NR*	100% female						16 (52)	(72, 70)
75.7% partnered									
Lengacher ⁴³ (United States)	Breast	Mean age, 57.5 years	RCT	CARS	CARS	Contemporary CBT	No	Face to face	Group
	No	72.6% white	2				No	6	84
	Stage 0-3	100% female						7	(82, no FU assessment)
% partnered = NR									
Herschbach ⁴⁴ (Germany)	Mixed	Mean age, 53.7 years	CT	FoP-Q	FoP-Q	Traditional CBT	Yes	Face to face	Group
	Yes	% white = NR	3			Other	Yes	4	265
	Mixed	83% female						3 (55)	(253, 253)
77.9% partnered									
Shields ⁴⁵ (United States)	Breast	Mean age, 44.1 years	RCT	CARS	CARS	Traditional CBT	No	Face to face	Individual
	No	97.5% white	2				No	1	45
	Stage 1-3	100% female						5 (14)	(44, 44)
% partnered = NR									
Crane-Okada ⁴⁶ (United States)	Breast	Mean age, 65.6 years	RCT	FCQ	FCQ	Contemporary CBT	No	Face to face	Group
	No	79% white	2				No	12	49
	NR	100% female						12 (18)	(41, 41)
41.7% partnered									
Heinrichs ⁴⁷ (Germany)	Breast or gynecologic	Mean age, 52.2 years	RCT	FoP-Q	FoP-Q	Traditional CBT	No	Face to face	Group
	Yes	% white = NR	2				No	4	90
	Stage 1-3	100% female						8 (69)	(72, 72)
100% partnered									
Humphris ⁴⁸ (United Kingdom)	Oropharyngeal	Mean age, 58.8 years	RCT	WOC	WOC	Traditional CBT	No	Face to face	Individual
	No	% white = NR	2				Yes	6	90
	Mixed	29% female						17 (39)	(87, 87)
% partnered = NR									

(continued on following page)

TABLE 1. Study Characteristics (continued)

Study (country)	Cancer Type; Cancer Present (yes/no); Stage	Demographic Characteristics	Study Design; No. of Arms	FCR Measure	Intervention Type*	FCR Severity as Inclusion Criteria; FCR as Primary Outcome	Delivery Mode; No. of Sessions; Duration, Weeks (FU)†	Treatment Format; Initial No.; Analyzed No. (post, FU)
Germino ⁴⁹ (United States)	Breast cancer	Mean age, 44 years	RCT	CARS	Traditional CBT	No	Self-directed	Individual
	No	62.6% white	2			No	4	313
	Stage 1-4	100% female					22 (39)	(no postassessment, 313)
		% partnered = NR						
Bannaasan ⁵⁰ (Thailand)	Breast	Mean age, 51.7 years	RCT	CARS – overall fear	Other	No	Face to face	Group
	No	% white = NR	2			Yes	4	60
	Stage 1-3	100% female					2 (6)	(59, 59)
		73.4% partnered						
Bower ⁵¹ (United States)	Breast	Mean age, 46.8 years	RCT	QLACS	Contemporary CBT	No	Face to face	Group
	No	76.1% white	2			No	6	71
	NR	100% female					8 (19)	(71, 71)
		64.6% partnered						
Dodds ⁵² (United States)	Breast	Mean age, 55.3 years	RCT	FCRI	Contemporary CBT	No	Face to face	Group
	No	82.1% white	2			No	8	33
	1-4	100% female					8 (12)	(28, 28)
		42.9% partnered						
Sterba ⁵³ (United States)	Breast	Mean age, 55.6 years	RCT	ASC	Other	No	Self-directed	Individual
	No	70% white	2			No	1	92
	Stage 1-3	100% female					14	(88, no FU assessment)
		64% partnered						
Dieng ⁵⁴ (Australia)	Melanoma	Mean age, 56.6 years	RCT	FCRI	Other	No	Telephone	Individual
	No	% white = NR	2			No	6	164
	Stage 0-2	45% female					6 (31)	(151, 151)
		84.8% partnered						
Lengacher ⁵⁵ (United States)	Breast	Mean age, 56.6 years	RCT	CARS	Contemporary CBT	No	Face to face	Group
	No	69.4% white	2			No	6	322
	Stage 0-3	100% female					6 (12)	(299, 299)
		64.4% partnered						

(continued on following page)

TABLE 1. Study Characteristics (continued)

Study (country)	Cancer Type; Cancer Present (yes/no); Stage	Demographic Characteristics	Study Design; No. of Arms	FCR Measure	Intervention Type*	FCR Severity as Inclusion Criteria; FCR as Primary Outcome	Delivery Mode; No. of Sessions; Duration, Weeks (FU)†	Treatment Format; Initial No.; Analyzed No. (post, FU)
Otto ⁵⁶ (United States)	Breast	Mean age, 56.9 years	RCT	CARS – overall fear and death worries	Other	No	Online, self-directed	Individual
	No	86.6% white	2			Yes	NR	67
	Stage 0-4	100% female					6	(no postassessment, 67)
		95.5% partnered						
Merckaert ⁵⁷ (Belgium)	Breast	Mean age, 50.6 years	RCT	FCRI	Traditional CBT	No	Face to face	Group
	No	% white = NR	2			No	15	170
	Stage 1-3	100% female					26	(159, no FU assessment)
		44% partnered						
Butow ⁵⁸ (Australia)	Mixed	Mean age, 52.8 years	RCT	FCRI	Contemporary CBT	Yes	Face to face	Individual
	No	% white = NR	2			Yes	5	222
	Stage 0-4	95% female					10 (23)	(173, 173)
		62% partnered						
Lichtenhal ⁵⁹ (United States)	Breast	Mean age, 55.2 years	RCT	CARS	Traditional CBT	No	Computerized	Individual
	No	73.7% white	2			Yes	8	110
	Stage 0-3	100% female					8 (21)	(110, 100)
		60.3% partnered						
Manne ⁶⁰ (United States)	Gynecologic	Mean age, 55.3 years	RCT	CARS – overall fear	Traditional CBT	No	Face to face	Individual
	Yes	79.0% white	3		Other	No	7	352
	Stage 1-4	100% female					9 (79)	(352, 352)
		67.3% partnered						
van de Wal ⁶¹ (the Netherlands)	Mixed	Mean age, 58.8 years	RCT	CWS, FCRI	Traditional CBT	Yes	Face to face, online	Individual
	No	% white = NR	2			Yes	8	88
	NR	53% female					13	(88, no FU assessment)
		82.9% partnered						

(continued on following page)

TABLE 1. Study Characteristics (continued)

Study (country)	Cancer Type; Cancer Present (yes/no); Stage	Demographic Characteristics	Study Design; No. of Arms	FCR Measure MAX-PC- FCR	Intervention Type*	FCR Severity as Inclusion Criteria; FCR as Primary Outcome	Delivery Mode; No. of Sessions; Duration, Weeks (FU)†	Treatment Format; Initial No.; Analyzed No. (post, FU)
Victorson ⁶² (United States)	Prostate	Mean age, 70.2 years	RCT	MAX-PC-FCR	Contemporary CBT	No	Face to face	Group
	Yes	95.1% white	2			No	8	43
	NR	0% female					8 (12)	(38, 31)
		82.7% partnered						
Gonzalez-Hernandez ⁶³ (Spain)	Breast	Mean age, 49.4 years	RCT	FCRI – triggers, distress, coping and insight	Contemporary CBT	No	Face to face	Group
	No	% white = NR	2			No	8	56
	Stage 1-4	100% female					8 (26)	(56, 56)
		% partnered = NR						
Tomel ⁶⁴ (Canada)	Mixed	Mean age, 55 years	RCT	FCRI	Traditional CBT	Yes	Face to face	Individual
	No	95.8% white	2			Yes	6	25
	Stage 1-3	100% female					6 (19)‡	(24, 24)
		79.2% partnered						
Open trials								
Chambers ⁶⁵ (Australia)	Prostate	Mean age, 67 years	OT	MAX-PC-FCR	Contemporary CBT	No	Face to face	Group
	Yes	% white = NR	1			No	8	19
	NR	0% female					8 (21)	(12, 12)
		84% partnered						
Lebel ⁶⁶ (Canada)	Breast, ovarian	Mean age, 54.8 years	OT	FRQ	Traditional CBT	Yes	Face to face	Group
	No	80.8% white	1			Yes	6	56
	Stage 1-3	100% female					6 (19)	(41, 37)
		58.9% partnered						
Seitz ⁶⁷ (Germany)	Mixed	Mean age, 27.3 years	OT	FoP-SF	Traditional CBT	No	Online	Individual
	No	% white = NR	1			Yes	10	28
	NR	70% female					5 (18)	(20, 14)
		50% partnered						

(continued on following page)

TABLE 1. Study Characteristics (continued)

Study (country)	Cancer Type; Cancer Present (yes/no); Stage	Demographic Characteristics	Study Design; No. of Arms	FCR Measure	Intervention Type*	FCR Severity as Inclusion Criteria; FCR as Primary Outcome	Delivery Mode; No. of Sessions; Duration, Weeks (FU)†	Treatment Format; Initial No.; Analyzed No. (post, FU)
Smith ⁶⁸ (Australia)	Mixed	Mean age, 48 years	OT	FCRI	Contemporary CBT	Yes	Face to face	Individual
	No	% white = NR	1			Yes	5	8
	NR	100% female					10 (18)	(7, 2)
		75% partnered						
Arch ⁶⁹ (United States)	Mixed	Mean age, 53.52 years	OT	CARS – overall fear	Contemporary CBT	No	Face to face	Group
	No	97.4% white	1			No	7	42
	Stage 0-4	92.9% female					8 (21)	(NR)
		61.5% partnered						
Morimoto ⁷⁰ (Japan)	Breast	Mean age, 55 years	OT	CARS	Traditional CBT	No	Face to face	Individual
	Yes	% white = NR	1			No	4	40
	Stage 0-4	100% female					5	(37, no FU assessment)
		78% partnered						
Lengacher ⁷¹ (United States)	Breast	Mean age, 57 years	OT	CARS	Contemporary CBT	No	Online	Individual
	No	93% white	1			No	6	15
	Stage 0-3	100% female					6	(13, no FU assessment)
		80% partnered						
Savard ⁷² (Canada)	Mixed	Mean age, 57.7 years	OT	FCRI	Traditional CBT	No	Face to face	Group
	Yes	100% white	1			Yes	4	38
	NR	94.7% female					8	(38)
		57.9% partnered						
Davidson ¹⁸ (United Kingdom)	Breast	Mean age, 60.0 years	OT	FCRI	Traditional CBT	Yes	Telephone	Individual
	No		1			Yes	1	16
	Stage 1-3						N/A (1)	(12)

Abbreviations: ASC, Assessment of Survivor Concerns; CARS, Concerns About Recurrence Scale; CBT, cognitive behavioral therapy; CT, controlled trial; CWS, Cancer Worry Scale; FCQ, Fear of Recurrence Scale; FCRI, Fear of Cancer Recurrence Inventory; FoP-Q, Fear of Progression Questionnaire; FoP-Q-SF, Fear of Progression Questionnaire-Short Form; FRQ, Fear of Recurrence Questionnaire; FU, follow-up; MAX-PC-FCR, Fear of Cancer Recurrence Subscale of the Memorial Anxiety Scale for Prostate Cancer; N/A, not available; NR, not reported; OT, open trial; QLACS, Quality of Life in Adult Cancer Survivors; RCT, randomized controlled trial; WOC, Worry of Cancer Scale.

*Interventions were classified into psychotherapeutic traditions on the basis of the strategies described. If an intervention combined strategies from more traditions, the intervention was assigned the psychotherapeutic tradition to which the strategies primarily belonged. If there was an insufficient description of therapies, original treatment protocols or studies were consulted. Classification was conducted by two authors and agreement was reached by discussion.

†Intervention duration: time from pre- to postassessment and time to FU.

‡Data for intervention and controls combined at follow-up.

TABLE 2. Pooled Postintervention and Follow-Up Effects of Psychological Interventions on Fear of Cancer Recurrence Among Survivors of Cancer

Effect	Sample Size		Heterogeneity*				Global Effect Size				
	K	No.	Q	df	P	I ²	Hedges's g†	95% CI	P	Failsafe No.‡	Criterion§
Postintervention											
Overall combined effect	21	2,163	38.9	20	.007	48.6	0.33	0.20 to 0.46	< .001	255	115
Cancer type: breast	12	1,067	24.2	11	.012	54.5	0.34	0.14 to 0.53	.010	64	70
Cancer type: other/mixed	9	1,096	14.4	8	.071	44.6	0.32	0.15 to .49	< .001	54	55
Cancer present	5	659	9.4	4	.050	57.8	0.27	0.03 to 0.52	.031	9	35
Disease free	16	1,504	26.6	15	.032	43.6	0.35	0.21 to 0.50	< .001	150	90
Study design: RCT	19	1,848	30.6	18	.032	41.2	0.33	0.20 to 0.46	< .001	200	105
Study design: CT	2	315	6.5	1	.011	84.7	0.36	-0.30 to 1.02	.283	—	—
Format: individual	9	949	14.7	8	.066	45.5	0.28	0.09 to 0.47	.003	29	55
Format: group	12	1,214	24.1	11	.012	54.4	0.37	0.19 to 0.55	< .001	98	70
Delivery: face to face	18	1,835	32.6	17	.013	47.9	0.38	0.24 to 0.51	< .001	234	110
Delivery: other	3	328	3.1	2	.204	37.2	0.10	-0.19 to 0.38	.510	—	—
FCR as primary target	8	908	20.0	7	.006	65.0	0.44	0.20 to 0.67	< .001	68	50
FCR as secondary target	13	1,255	18.0	12	.116	33.3	0.26	0.12 to 0.41	< .001	50	75
FCR level as inclusion criterion	4	544	8.9	3	.030	66.5	0.36	0.09 to 0.64	.010	13	30
FCR level not inclusion criterion	17	1,641	28.8	16	.025	44.5	0.32	0.17 to 0.46	< .001	137	95
Therapy: traditional CBT	9	1,025	11.7	8	.116	31.5	0.24	0.08 to 0.39	.003	25	55
Therapy: contemporary CBT	9	848	6.1	8	.642	0.0	0.42	0.29 to 0.56	< .001	66	55
Therapy: other	3	290	15.0	2	.001	86.6	0.35	-0.32 to 1.02	.310	—	—
FCR measure: CARS	6	792	13.4	5	.020	62.7	0.38	0.15 to 0.61	.001	28	40
FCR measure: FCRI	7	659	8.3	6	.216	27.8	0.33	0.10 to 0.55	.005	22	45
Follow-up											
Overall combined effect	18	2,044	26.8	17	.061	36.6	0.28	0.17 to 0.40	< .001	158	100
Cancer type: breast	11	1,109	13.9	10	.176	28.2	0.36	0.20 to 0.52	< .001	77	65
Cancer type: other/mixed	7	936	10.9	6	.091	45.1	0.20	0.02 to 0.37	.031	9	45
Cancer present	5	612	10.1	4	.039	60.3	0.16	-0.11 to 0.43	.235	—	—
Disease free	13	1,432	15.1	12	.235	20.1	0.33	0.20 to 0.45	< .001	107	75
Study design: RCT	16	1,769	27.8	16	.034	42.4	0.29	0.15 to 0.43	< .001	100	90
Study design: CT	2	413	0.8	1	.386	0.0	0.43	0.22 to 0.64	< .001	—	—
Format: individual	8	1,121	6.7	7	.463	0.0	0.19	0.07 to 0.31	.002	17	50
Format: group	10	923	15.8	9	.072	42.9	0.36	0.18 to 0.55	< .001	59	60
Delivery: face to face	14	1,417	25.8	13	.018	49.7	0.31	0.15 to 0.47	< .001	96	80
Delivery: other	4	627	0.4	3	.933	0.0	0.23	0.07 to 0.38	.006	4	30
FCR as primary target	8	1,135	14.0	7	.051	50.1	0.36	0.19 to 0.54	< .001	68	50
FCR as secondary target	10	910	9.6	9	.387	5.9	0.19	0.01 to 0.33	.009	11	60
FCR level as inclusion criterion	2	362	0.4	1	.505	0.0	0.43	0.24 to 0.62	< .001	—	—
FCR level not inclusion criterion	16	1,683	23.3	15	.079	35.5	0.26	0.12 to 0.39	< .001	88	90
Therapy: traditional CBT	7	1,025	11.1	6	.086	45.8	0.22	0.04 to 0.40	.015	17	45
Therapy: contemporary CBT	8	744	2.6	7	.902	0.0	0.30	0.16 to 0.45	< .001	20	50

(continued on following page)

TABLE 2. Pooled Postintervention and Follow-Up Effects of Psychological Interventions on Fear of Cancer Recurrence Among Survivors of Cancer (continued)

Effect	Sample Size		Heterogeneity*				Global Effect Size				
	K	No.	Q	df	P	I ²	Hedges's <i>g</i> †	95% CI	P	Failsafe No.‡	Criterion§
Therapy: other	3	276	11.4	2	.003	82.4	0.54	−0.08 to 1.16	.088	—	—
FCR measure: CARS	7	1,086	19.7	6	.003	69.5	0.34	0.10 to 0.57	.005	35	45
FCR measure: FCRI	4	382	1.1	3	.775	0.0	0.22	0.02 to 0.42	.031	0	30

Abbreviations: CARS, Concerns About Recurrence Scale; CBT, cognitive behavioral therapy; CT, controlled trial; FCR, fear of cancer recurrence; FCRI, Fear of Cancer Recurrence Inventory; RCT, randomized controlled trial.

*Q-statistic: *P* values < .1 are taken to suggest heterogeneity. I² statistic: 0% (no heterogeneity), 25% (low heterogeneity), 50% (moderate heterogeneity), and 75% (high heterogeneity).

†Effect size: Hedges's *g*. A positive value indicates an effect size in the hypothesized direction. All effect sizes were combined using a random effects model. Conventions: small (0.2), medium (0.5), or large (0.8).²⁷

‡Number of nonsignificant studies that would bring the *P* value to nonsignificant (*P* > .05).

§A failsafe number that exceeds the criterion (5 × *K* + 10) indicates a robust result.³⁷

||*K* < 23, as two studies did not assess outcomes at postintervention.

found no statistically significant effect ($g = 0.15$; $P = .44$; no additional data shown).⁷⁰

Main Effects

Results of the meta-analyses are listed in Table 2 and illustrated with forest plots in Figure 2 and the Data Supplement. The overall combined postintervention ES was statistically significant and of small magnitude ($g = 0.33$; 95% CI, 0.20 to 0.46; $P < .001$). There were no indications of publication bias, and the failsafe number for effects at post-treatment (failsafe $n = 255$) exceeded the criterion ($n = 115$), which suggested a robust result. The overall combined effect at follow-up was statistically significant and only slightly smaller than at postintervention ($g = 0.28$; $P < .001$). Again, there were no indications of publication bias, and follow-up results seemed to be robust.

Heterogeneity

Statistically significant Q tests and moderate I² values for both postintervention (48.6%) and follow-up results (36.6%; Table 2) suggested some degree of variability in ESs beyond sampling error.

Subgroup and Moderation Analyses

As shown in Table 2, when examining the results of the prespecified study subgroups—categorized according to cancer type, disease status, study design, format, delivery, FCR as primary or secondary target, FCR level as inclusion criterion or not, and psychotherapeutic framework—ESs were, with few exceptions, generally comparable across subgroups of studies. Almost all ESs were of small magnitude at both postintervention and follow-up. Results of the meta-regression analyses are listed in Table 3. At post-intervention, effects of contemporary CBTs ($g = 0.42$) were larger than those of traditional CBTs ($g = 0.24$; $\beta = .22$; $P = .018$). At follow-up, larger effects were associated with

shorter time to follow-up (in weeks; $\beta = -.01$; $P = .027$) and with group-based format compared with individual treatment format ($\beta = .18$; $P = .041$; Data Supplement). Changes in raw scores for the two most frequently used FCR measures—Concerns About Recurrence Scale and Fear of Cancer Recurrence Inventory—corresponded to mean differences of 1.3 (95% CI, 0.4 to 2.3; Concerns About Recurrence Scale overall fear) and 2.2 (95% CI, 1.4 to 3.1; Fear of Cancer Recurrence Inventory severity subscale; Data Supplement).

Risk of Bias

Before negotiation, the two raters (L.S. and G.O.) agreed on 150 (81.5%) of 184 risk of bias ratings, and the interrater agreement (κ ³⁹) for the individual domains ranged from almost perfect (0.91; random sequence allocation) to fair (0.39; treatment integrity). Final negotiated results of risk of bias assessments for each study are shown in Figure 3 (for additional details, see the Data Supplement). No associations were found between total risk of bias scores and ESs at postintervention and follow-up (Table 3).

Overall Quality of Meta-Analytic Evidence

The overall evidence for RCTs was qualified using GRADE.⁴¹ Overall, moderate quality of evidence demonstrates that psychological intervention may reduce FCR symptom compared with control conditions. The level of evidence for RCTs was downgraded to moderate as a result of concerns regarding inconsistency—that is, methodologic and clinical heterogeneity and inability to identify the reasons for heterogeneity—and indirectness—that is, that a considerable proportion of studies ($K = 13$) had FCR as secondary outcome, most studies included women only, and the majority of studies focused on FCR in cancer survivors, not fear of progression in patients with cancer




FIG 2. Forest plot of effect sizes (ESs; Hedges's *g*) for effects at postintervention of psychological interventions on fear of cancer recurrence (FCR). (*) Weights are from random effects analysis.

present. Overall, no serious concerns were found for risk of bias, imprecision, and publication bias.

DISCUSSION

The primary objective of the current study was to evaluate the efficacy of psychological interventions in alleviating FCR symptoms among patients with and survivors of cancer. Twenty-three controlled studies were identified, revealing a statistically significant effect on FCR outcomes of a small magnitude ($g = 0.33$) immediately after intervention, which was largely maintained at follow-up ($g = 0.28$), on average more than 7 months after the intervention. Results were robust with no indications of publication bias, which supported our hypothesis that psychological interventions would be efficacious relative to controls in reducing FCR symptoms. These findings are encouraging, given that managing FCR is a common unmet need among survivors of cancer⁶ and, when persistent and excessive, leaves the

individual at risk of depression, impaired daily functioning, using unnecessary health assessments, and reduced quality of life.^{1,2} Furthermore, current findings point to lasting effects of FCR interventions beyond the immediate completion of the intervention. This finding is particularly relevant, as unmanaged FCR tends to stabilize over time.^{2,7} Here, it should be noted that follow-up times varied from 6 weeks to 78 weeks across studies and that meta-regression demonstrated that longer time to follow-up assessment was associated with a statistically significantly smaller effect. Number of sessions ranged from one to 15, with an average of 6.6 sessions, but no associations were found between the number of sessions and ES either at postintervention or at follow-up.

A secondary aim was to explore the possible influence of between-study differences. The larger effect found at postintervention for contemporary CBTs ($g = 0.42$) compared with traditional CBTs ($g = 0.24$) supports a hypothesis

TABLE 3. Moderators of Effects at Postintervention and Follow-Up: Results of Meta-Regression Analyses

Moderator	K	β^*	95% CI	P (two tailed)
Postintervention				
Cancer type: breast (referent: other)	21	0.01	-0.24 to 0.25	.969
FCR primary target (referent: secondary)	21	0.15	-0.10 to 0.39	.255
FCR level inclusion criterion (referent: not a criterion)	21	0.04	-0.25 to 0.33	.788
Format: group (referent: individual)	21	0.09	-0.16 to 0.34	.477
Delivery: face to face (referent: other)	21	0.28	-0.05 to 0.60	.094
Therapy: contemporary CBT (referent: traditional CBT)	18	0.22	0.04 to 0.41	.018
Gender: percent women in sample (range, 0% to 100%)	21	0.00	-0.01 to 0.01	.882
Time to postintervention assessment, weeks (range, 2-26)	21	-0.01	-0.03 to 0.01	.327
No. of sessions (range, 1-15)	21	0.01	-0.03 to 0.04	.673
Mean sample age, years (range, 44-70)	21	0.00	-0.03 to 0.03	.911
Risk of bias score (range, 1-13)	21	-0.01	-0.04 to 0.04	.984
FCR measure: CARS (referent: FCRI)	13	0.04	-0.25 to 0.34	.766
Follow-up				
Cancer type: breast (referent: other)	18	0.15	-0.06 to 0.37	.162
FCR primary target (referent: secondary)	18	0.16	-0.04 to 0.36	.115
FCR level inclusion criterion (referent: not a criterion)	18	0.18	-0.05 to 0.42	.124
Format: group (referent: individual)	18	0.18	0.01 to 0.36	.041
Delivery: face to face (referent: other)	18	-0.07	-0.31 to 0.17	.551
Therapy: contemporary CBT (referent traditional CBT)	15	0.07	-0.13 to 0.28	.486
Gender: percent women in sample (range, 0% to 100%)	18	0.00	-0.01 to 0.01	.377
Time to follow-up assessment, weeks (range, 6-78)	14	-0.01	-0.01 to -0.00	.027
No. of sessions (range, 1-12)	17	-0.02	-0.07 to 0.03	.435
Mean sample age, years (range, 44-70)	18	-0.01	-0.03 to 0.01	.522
Risk of bias score (range, 1-13)	18	0.02	-0.01 to 0.06	.130
FCR measure: CARS (referent: FCRI)	11	0.10	-0.23 to 0.43	.566

Abbreviations: CARS, Concerns About Recurrence Scale; CBT, cognitive behavioral therapy; FCR, fear of cancer recurrence; FCRI, Fear of Cancer Recurrence Inventory.

*Maximum likelihood method.

that FCR may be particularly responsive to contemporary therapies that aim to change the way in which individuals relate to their inner experiences by focusing on cognitive processing and metacognitions in FCR—for example, worry, rumination, or attentional bias.^{78,79} The difference no longer reached statistical significance at follow-up, mainly because of smaller ESs of contemporary CBTs at follow-up, which perhaps suggests that meta-cognitive skills learned in contemporary CBTs require booster sessions or materials to maintain long-term effects. Larger effects at follow-up were associated with shorter time to follow-up and with a group-based format compared with an individual treatment format. We have no clear explanation for the latter finding, which could be explored in future research.

All remaining moderation analyses failed to reach statistical significance. It has previously been found that newly diagnosed patients with cancer and younger survivors are more prone to experiencing high levels of FCR,² but neither

the presence of cancer, nor age was associated with overall intervention effect. Given the relatively small number of studies in the moderation analyses, which likely compromised our statistical power, two results should be noted when considering the numerical difference in ESs. First, the ES obtained at post-treatment with treatment delivered face to face was numerically larger ($g = 0.38$) than treatments that were delivered by other means (eg, telephone or Web based; $g = 0.10$). Only three studies used such other delivery means and results should be interpreted accordingly; the small number of studies demonstrated that delivery methods other than traditional face-to-face treatments are largely unexplored within the context of FCR. Internet-based interventions have previously been shown to be effective for anxiety disorders and fear-related conditions⁸⁰ and have obtained equivalent effects to face-to-face treatments.⁸¹ It remains a question of whether this could be the case for FCR as well. Second, studies with FCR as their primary target obtained larger ESs at both postintervention

Random sequence generation	-	?	-	?	+	+	+	+	+	+	?	?	+	?	+	+	+	+	?	+	+	+	
Allocation concealment	-	?	-	?	+	?	+	?	?	?	?	?	?	?	+	+	?	?	+	+	+	+	
Blinding of outcome assessment	-	?	?	?	-	?	+	?	?	?	?	?	?	?	?	?	?	?	+	?	+	?	
Accounting for attrition	-	+	-	+	-	+	+	?	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Selective reporting	?	-	?	?	?	?	?	?	?	?	?	?	?	?	-	-	+	?	?	?	+	+	
Treatment integrity	?	+	?	?	+	?	?	+	+	-	?	?	?	N/A	?	N/A	?	N/A	?	?	+	+	
Conflict of interest	?	?	?	?	-	?	?	-	?	?	?	?	+	+	+	?	?	?	?	+	-	+	
Bias in sampling and dropout	-	+	-	+	?	-	?	+	?	+	+	?	+	+	+	?	?	?	?	+	?	+	
	Cameron et al, 2007	Lengacher et al, 2009	Herschbach et al, 2010	Shields et al, 2010	Heinrichs et al, 2012	Crane-Okada et al, 2012	Humphris and Rogers, 2012	Dieng et al, 2012	Gerrino et al, 2013	Bannaasan et al, 2015	Bower et al, 2015	Dodds et al, 2015	Sterba et al, 2015	Lengacher et al, 2016	Otto et al, 2016	Merckaert et al, 2017	Lichtenthal et al, 2017	van de Wal et al, 2017	Victorson et al, 2017	Manne et al, 2017	Butow et al, 2017	Gonzalez-Hernandez et al, 2018	Toméi et al, 2018

FIG 3. Risk of bias. Blue box with plus sign indicates a low risk of bias; red box with question mark indicates an unclear risk of bias; teal box with minus sign indicates a high risk of bias. N/A, not applicable.

and follow-up ($g = 0.42; 0.36$) than studies examining FCR as a secondary target ($g = 0.26; 0.19$). This finding should be further explored as the number of treatment studies increases, sufficiently powering analyses to test whether treatments with FCR as their primary target are superior in reducing FCR symptoms compared with generalized interventions. In addition, only four studies included participants on the basis of their FCR symptom levels and it is unclear to what degree this may have influenced results.

Robust but relatively small effects point to a number of potential implications, both clinically and for future research. Establishing the efficacy of psychological interventions for FCR should also concern which treatment components may be most efficacious or which processes drive the effect. Fardell et al⁷⁸ have suggested a number of key maintaining processes of FCR, resulting in a theoretical model with dysfunctional cognitive processes at its core. The authors suggest that particular treatment components from contemporary CBTs, including metacognitive therapy⁸² and acceptance and commitment therapy,⁸³ are well suited for targeting such processes. Future treatment trials should not only establish the efficacy of their treatment, but also investigate which components are most change potent. One approach could be the Multiphase Optimization Strategy,⁸⁴ a systematic method for exploring the main and interactive effects of treatment components and investigating select treatment components in a factorial design where all possible combinations of components are evaluated. Furthermore, the dose needed for effective treatment of FCR is likely not identical for all individuals and intervention researchers are increasingly interested in ways to individually tailor psychotherapy (eg, Fisher and Boswell).⁸⁵ Existing therapies already suggest conducting a thorough individual case formulation⁵⁸; however, to date, treatment programs for FCR have not outlined or investigated markers—for example, time since diagnosis, severity of FCR, or level or type of dysfunctional cognitive processes—suggestive of including or

abandoning certain treatment components or increasing or decreasing the dose. Theoretical formulations of FCR⁷⁸ could guide researchers in identifying relevant markers to investigate.

Our results should be viewed in light of limitations that pertain to the methodology of the included studies and between-study heterogeneity, noting that overall strength of the evidence was downgraded to moderate. Many studies suffered from the risk of selective reporting. Although evaluating the effect within the different categories pertaining to each of the identified moderators, between-study heterogeneity for most categories remained moderate to large. This could indicate potentially unidentified variables that are responsible for systematic variation. Finally, it should be noted that all but four authors have contributed to the studies included in the present review, which might raise concerns regarding bias. However, this may be less of an issue as the review was preregistered; all authors agreed to the final protocol; the first, second, and corresponding authors (N.M.T., M.S.O., and R.Z.) have not yet published any intervention studies on FCR; and screening and data extraction was performed by authors who had not been principle investigators of any of the reviewed studies.

In conclusion, to our knowledge, this is currently the most comprehensive systematic review and meta-analysis of the effect of controlled psychological intervention studies specifically on FCR outcomes. Twenty-three CTs were located, revealing a statistically significant effect on FCR outcomes of a small magnitude that was largely maintained at follow-up. Psychological interventions therefore seem to be efficacious in reducing FCR symptoms. Future trials should focus on targeted interventions for FCR, include participants on the basis of high levels of FCR, and investigate how to further optimize interventions—for instance, by exploring the effect of different treatment components and tailoring the intervention to the individual's FCR symptoms.

AFFILIATIONS

- ¹Aarhus University, Aarhus, Denmark
²International Psycho-Oncology Society Fear of Cancer Recurrence Special Interest Group, Toronto, Ontario, Canada
³Technical University of Munich, Munich, Germany
⁴Queen's University, Kingston, Ontario, Canada
⁵University of St Andrews, St Andrews, United Kingdom
⁶University of Ottawa, Ottawa, Ontario, Canada
⁷McGill University, Montréal, Québec, Canada
⁸Radboud University Medical Centre, Nijmegen, the Netherlands
⁹University of Sydney, Sydney, NSW, Australia
¹⁰Ingham Institute for Applied Medical Research and University of New South Wales, Sydney, NSW, Australia
¹¹Université du Québec à Chicoutimi, Saguenay, Québec, Canada
¹²Aarhus University Hospital, Aarhus, Denmark

CORRESPONDING AUTHOR

Robert Zachariae, DMSc, Aarhus University Hospital, Bartholin's Allé 9, Blvd 1350, 8000 Aarhus C, Denmark; e-mail: bzach@aarhus.rm.dk.

PRIOR PRESENTATION

Presented at the 20th World Congress of Psycho-Oncology, Hong Kong, Special Administrative Region, People's Republic of China, October 29-November 2, 2018.

REFERENCES

1. Lebel S, Ozakinci G, Humphris G, et al: Current state and future prospects of research on fear of cancer recurrence. *Psychooncology* 26:424-427, 2017
2. Simard S, Thewes B, Humphris G, et al: Fear of cancer recurrence in adult cancer survivors: A systematic review of quantitative studies. *J Cancer Surviv* 7: 300-322, 2013
3. Goerling U (ed): Fear of progression, in *Psycho-oncology*. New York, NY, Springer-Verlag Publishing, 2014, pp 11-29
4. Lee-Jones C, Humphris G, Dixon R, et al: Fear of cancer recurrence: A literature review and proposed cognitive formulation to explain exacerbation of recurrence fears. *Psychooncology* 6:95-105, 1997
5. Lebel S, Ozakinci G, Humphris G, et al: From normal response to clinical problem: Definition and clinical features of fear of cancer recurrence. *Support Care Cancer* 24:3265-3268, 2016
6. Baker F, Denniston M, Smith T, et al: Adult cancer survivors: How are they faring? *Cancer* 104:2565-2576, 2005 (suppl)
7. Koch L, Jansen L, Brenner H, et al: Fear of recurrence and disease progression in long-term (≥ 5 years) cancer survivors: A systematic review of quantitative studies. *Psychooncology* 22:1-11, 2013
8. Thewes B, Zachariae R, Christensen S, et al: The Concerns About Recurrence Questionnaire: Validation of a brief measure of fear of cancer recurrence amongst Danish and Australian breast cancer survivors. *J Cancer Surviv* 9:68-79, 2015
9. Thewes B, Butow P, Bell ML, et al: Fear of cancer recurrence in young women with a history of early-stage breast cancer: A cross-sectional study of prevalence and association with health behaviours. *Support Care Cancer* 20:2651-2659, 2012
10. Sharpe L, Thewes B, Butow P: Current directions in research and treatment of fear of cancer recurrence. *Curr Opin Support Palliat Care* 11:191-196, 2017
11. Maheu C, Lebel S, Courbasson C, et al: Protocol of a randomized controlled trial of the fear of recurrence therapy (FORT) intervention for women with breast or gynecological cancer. *BMC Cancer* 16:291, 2016
12. van Helmond SJ, van der Lee ML, de Vries J: Study protocol of the CAREST-trial: A randomised controlled trial on the (cost-) effectiveness of a CBT-based online self-help training for fear of cancer recurrence in women with curatively treated breast cancer. *BMC Cancer* 16:527, 2016
13. Tomei C, Lebel S, Maheu C, et al: Addressing fear of recurrence: Improving psychological care in cancer survivors. *Support Care Cancer* 24:2815-2818, 2016
14. Ahmed K, Marchand E, Williams V, et al: Development and pilot testing of a psychosocial intervention program for young breast cancer survivors. *Patient Educ Couns* 99:414-420, 2016
15. Fisher PL, Byrne A, Salmon P: Metacognitive therapy for emotional distress in adult cancer survivors: A case series. *Cognit Ther Res* 41:891-901, 2017
16. Dieng M, Kasparian NA, Mireskandari S, et al: Psychoeducational intervention for people at high risk of developing another melanoma: A pilot randomised controlled trial. *BMJ Open* 7:e015195, 2017
17. Wagner LI, Duffey J, Penedo F, et al: Coping strategies tailored to the management of fear of recurrence and adaptation for E-health delivery: The Fortitude intervention. *Cancer* 123:906-910, 2017
18. Davidson J, Malloch M, Humphris G: A single-session intervention (the Mini-AFTERc) for fear of cancer recurrence: A feasibility study. *Psychooncology* 27: 2668-2670, 2018
19. Hall DL, Luberto CM, Philpotts LL, et al: Mind-body interventions for fear of cancer recurrence: A systematic review and meta-analysis. *Psychooncology* 27: 2546-2558, 2018
20. Mast ME: Survivors of breast cancer: Illness uncertainty, positive reappraisal, and emotional distress. *Oncol Nurs Forum* 25:555-562, 1998
21. Hilton BA: The relationship of uncertainty, control, commitment, and threat of recurrence to coping strategies used by women diagnosed with breast cancer. *J Behav Med* 12:39-54, 1989

SUPPORT

Supported in part by Danish Cancer Society Grant No. R150-A10080.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST AND DATA AVAILABILITY STATEMENT

Disclosures provided by the authors and data availability statement (if applicable) are available with this article at DOI <https://doi.org/10.1200/JCO.19.00572>.

AUTHOR CONTRIBUTIONS

Conception and design: Nina M. Tauber, Mia S. O'Toole, Andreas Dinkel, Sophie Lebel, Christine Maheu, Gozde Ozakinci, Judith Prins, Louise Sharpe, Allan "Ben" Smith, Belinda Thewes, Sébastien Simard, Robert Zachariae

Administrative support: Nina M. Tauber

Provision of study materials or patients: Judith Prins

Collection and assembly of data: Nina M. Tauber, Jacqueline Galica, Christine Maheu, Judith Prins, Louise Sharpe, Allan "Ben" Smith, Belinda Thewes, Sébastien Simard, Robert Zachariae

Data analysis and interpretation: Nina M. Tauber, Mia S. O'Toole, Andreas Dinkel, Gerry Humphris, Sophie Lebel, Christine Maheu, Gozde Ozakinci, Judith Prins, Belinda Thewes, Sébastien Simard, Robert Zachariae

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

22. Eisenberg SA, Kurita K, Taylor-Ford M, et al: Intolerance of uncertainty, cognitive complaints, and cancer-related distress in prostate cancer survivors. *Psychooncology* 24:228-235, 2015
23. Mutsaers B, Jones G, Rutkowski N, et al: When fear of cancer recurrence becomes a clinical issue: A qualitative analysis of features associated with clinical fear of cancer recurrence. *Support Care Cancer* 24:4207-4218, 2016
24. Liberati A, Altman DG, Tetzlaff J, et al: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. *BMJ* 339:b2700, 2009
25. Booth A, Clarke M, Dooley G, et al: The nuts and bolts of PROSPERO: An international prospective register of systematic reviews. *Syst Rev* 1:2, 2012
26. Sackett DL, Rosenberg WMC, Gray JAM, et al: Evidence based medicine: What it is and what it isn't. *BMJ* 312:71-72, 1996
27. Cohen J: *Statistical Power Analysis for the Behavioral Sciences*. Hillsdale, NJ, Lawrence Erlbaum Associates, 1988
28. Hedges L, Olkin I: *Statistical Methods for Meta-Analysis*. New York, NY, Academic Press, 1985
29. Higgins JPT, Sally G (eds): Addressing reporting bias, in *Cochrane Handbook for Systematic Reviews of Interventions*. Hoboken, NJ, Wiley-Blackwell, 2008, pp 297-333
30. Poole C, Greenland S: Random-effects meta-analyses are not always conservative. *Am J Epidemiol* 150:469-475, 1999
31. Higgins JP, Thompson SG, Deeks JJ, et al: Measuring inconsistency in meta-analyses. *BMJ* 327:557-560, 2003
32. Ioannidis JP, Trikalinos TA: The appropriateness of asymmetry tests for publication bias in meta-analyses: A large survey. *CMAJ* 176:1091-1096, 2007
33. Copas J, Shi JQ: Meta-analysis, funnel plots and sensitivity analysis. *Biostatistics* 1:247-262, 2000
34. Deeks JJ, Macaskill P, Irwig L: The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. *J Clin Epidemiol* 58:882-893, 2005
35. Egger M, Davey Smith G, Schneider M, et al: Bias in meta-analysis detected by a simple, graphical test. *BMJ* 315:629-634, 1997
36. Duval S, Tweedie R: Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* 56:455-463, 2000
37. Rosenthal R: The "file-drawer problem" and tolerance for null results. *Psychol Bull* 86:638-641, 1979
38. Higgins JP, Altman DG, Gøtzsche PC, et al: The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 343:d5928, 2011
39. McHugh ML: Interrater reliability: The kappa statistic. *Biochem Med (Zagreb)* 22:276-282, 2012
40. Greenland S, O'Rourke K: On the bias produced by quality scores in meta-analysis, and a hierarchical view of proposed solutions. *Biostatistics* 2:463-471, 2001
41. Guyatt G, Oxman AD, Akl EA, et al: GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol* 64:383-394, 2011
42. Cameron LD, Booth RJ, Schlatter M, et al: Changes in emotion regulation and psychological adjustment following use of a group psychosocial support program for women recently diagnosed with breast cancer. *Psychooncology* 16:171-180, 2007
43. Lengacher CA, Johnson-Mallard V, Post-White J, et al: Randomized controlled trial of mindfulness-based stress reduction (MBSR) for survivors of breast cancer. *Psychooncology* 18:1261-1272, 2009
44. Herschbach P, Book K, Dinkel A, et al: Evaluation of two group therapies to reduce fear of progression in cancer patients. *Support Care Cancer* 18:471-479, 2010
45. Shields CG, Ziner KW, Bourff SA, et al: An intervention to improve communication between breast cancer survivors and their physicians. *J Psychosoc Oncol* 28:610-629, 2010
46. Crane-Okada R, Kiger H, Sugerman F, et al: Mindful movement program for older breast cancer survivors: A pilot study. *Cancer Nurs* 35:E1-E13, 2012
47. Heinrichs N, Zimmermann T, Huber B, et al: Cancer distress reduction with a couple-based skills training: A randomized controlled trial. *Ann Behav Med* 43:239-252, 2012
48. Humphris GM, Rogers SN: AFTER and beyond: Cancer recurrence fears and a test of an intervention in oropharyngeal patients. *Soc Sci Dent* 2:29-38, 2012
49. Germino BB, Mishel MH, Crandell J, et al: Outcomes of an uncertainty management intervention in younger African American and Caucasian breast cancer survivors. *Oncol Nurs Forum* 40:82-92, 2013
50. Bannaasan B, Pothiban L, Khampolsiri T, et al: Effects of Buddhist doctrine-based practice on fear of cancer recurrence and hopelessness: A randomized controlled trial. *Pac Rim Int J Nurs Res* 19:295-310, 2015
51. Bower JE, Crosswell AD, Stanton AL, et al: Mindfulness meditation for younger breast cancer survivors: A randomized controlled trial. *Cancer* 121:1231-1240, 2015
52. Dodds SE, Pace TW, Bell ML, et al: Feasibility of cognitively-based compassion training (CBCT) for breast cancer survivors: A randomized, wait list controlled pilot study. *Support Care Cancer* 23:3599-3608, 2015 [Erratum: *Support Care Cancer* 23:3609-3611, 2015]
53. Sterba KR, Armeson K, Franco R, et al: A pilot randomized controlled trial testing a minimal intervention to prepare breast cancer survivors for recovery. *Cancer Nurs* 38:E48-E56, 2015
54. Dieng M, Butow PN, Costa DS, et al: Psychoeducational intervention to reduce fear of cancer recurrence in people at high risk of developing another primary melanoma: Results of a randomized controlled trial. *J Clin Oncol* 34:4405-4414, 2016
55. Lengacher CA, Reich RR, Paterson CL, et al: Examination of broad symptom improvement resulting from mindfulness-based stress reduction in breast cancer survivors: A randomized controlled trial. *J Clin Oncol* 34:2827-2834, 2016
56. Otto AK, Szczyesny EC, Soriano EC, et al: Effects of a randomized gratitude intervention on death-related fear of recurrence in breast cancer survivors. *Health Psychol* 35:1320-1328, 2016
57. Merckaert I, Lewis F, Delevallez F, et al: Improving anxiety regulation in patients with breast cancer at the beginning of the survivorship period: A randomized clinical trial comparing the benefits of single-component and multiple-component group interventions. *Psychooncology* 26:1147-1154, 2017
58. Butow PN, Turner J, Gilchrist J, et al: Randomized trial of ConquerFear: A novel, theoretically based psychosocial intervention for fear of cancer recurrence. *J Clin Oncol* 35:4066-4077, 2017
59. Lichtenthal WG, Corner GW, Slivjak ET, et al: A pilot randomized controlled trial of cognitive bias modification to reduce fear of breast cancer recurrence. *Cancer* 123:1424-1433, 2017
60. Manne SL, Virtue SM, Ozga M, et al: A comparison of two psychological interventions for newly-diagnosed gynecological cancer patients. *Gynecol Oncol* 144:354-362, 2017
61. van de Wal M, Thewes B, Gielissen M, et al: Efficacy of blended cognitive behavior therapy for high fear of recurrence in breast, prostate, and colorectal cancer survivors: The SWORD study, a randomized controlled trial. *J Clin Oncol* 35:2173-2183, 2017
62. Victorson D, Hankin V, Burns J, et al: Feasibility, acceptability and preliminary psychological benefits of mindfulness meditation training in a sample of men diagnosed with prostate cancer on active surveillance: Results from a randomized controlled pilot trial. *Psychooncology* 26:1155-1163, 2017
63. Gonzalez-Hernandez E, Romero R, Campos D, et al: Cognitively-based compassion training (CBCT®) in breast cancer survivors: A randomized clinical trial study. *Integr Cancer Ther* 17:684-696, 2018

64. Tomei C, Lebel S, Maheu C, et al: Examining the preliminary efficacy of an intervention for fear of cancer recurrence in female cancer survivors: A randomized controlled clinical trial pilot study. *Support Care Cancer* 26:2751-2762, 2018
65. Chambers SK, Foley E, Galt E, et al: Mindfulness groups for men with advanced prostate cancer: A pilot study to assess feasibility and effectiveness and the role of peer support. *Support Care Cancer* 20:1183-1192, 2012
66. Lebel S, Maheu C, Lefebvre M, et al: Addressing fear of cancer recurrence among women with cancer: A feasibility and preliminary outcome study. *J Cancer Surviv* 8:485-496, 2014
67. Seitz DC, Knaevelsrud C, Duran G, et al: Efficacy of an internet-based cognitive-behavioral intervention for long-term survivors of pediatric cancer: A pilot study. *Support Care Cancer* 22:2075-2083, 2014
68. Smith A, Thewes B, Turner J, et al: Pilot of a theoretically grounded psychologist-delivered intervention for fear of cancer recurrence (Conquer Fear). *Psychooncology* 24:967-970, 2015
69. Arch JJ, Mitchell JL: An acceptance and commitment therapy (ACT) group intervention for cancer survivors experiencing anxiety at re-entry. *Psychooncology* 25:610-615, 2016
70. Momino K, Mitsunori M, Yamashita H, et al: Collaborative care intervention for the perceived care needs of women with breast cancer undergoing adjuvant therapy after surgery: A feasibility study. *Jpn J Clin Oncol* 47:213-220, 2017
71. Lengacher CA, Reich RR, Ramesar S, et al: Feasibility of the mobile mindfulness-based stress reduction for breast cancer (mMBSR(BC)) program for symptom improvement among breast cancer survivors. *Psychooncology* 27:524-531, 2018
72. Savard J, Savard MH, Caplette-Gingras A, et al: Development and feasibility of a group cognitive-behavioral therapy for fear of cancer recurrence. *Cognit Behav Pract* 25:275-285, 2018
73. Beck AT, Rush AJ, Shaw BF, et al: *Cognitive Therapy of Depression*. New York, NY, Wiley & Sons, 1979
74. Mennin DS, Ellard KK, Fresco DM, et al: United we stand: Emphasizing commonalities across cognitive-behavioral therapies. *Behav Ther* 44:234-248, 2013
75. Hayes SC, Luoma JB, Bond FW, et al: Acceptance and commitment therapy: Model, processes and outcomes. *Behav Res Ther* 44:1-25, 2006
76. Wells A, Matthews G: Modelling cognition in emotional disorder: The S-REF model. *Behav Res Ther* 34:881-888, 1996
77. Kabat-Zinn J: *Full Catastrophe Living: How to Cope With Stress, Pain and Illness Using Mindfulness Meditation*. New York, NY, Bantam Dell, 1990
78. Fardell JE, Thewes B, Turner J, et al: Fear of cancer recurrence: A theoretical review and novel cognitive processing formulation. *J Cancer Surviv* 10:663-673, 2016
79. Butow P, Kelly S, Thewes B, et al: Attentional bias and metacognitions in cancer survivors with high fear of cancer recurrence. *Psychooncology* 24:416-423, 2015
80. Domhardt M, Geblein H, von Rezori RE, et al: Internet- and mobile-based interventions for anxiety disorders: A meta-analytic review of intervention components. *Depress Anxiety* 36:213-224, 2019
81. Andersson G, Cuijpers P, Carlbring P, et al: Guided Internet-based vs. face-to-face cognitive behavior therapy for psychiatric and somatic disorders: A systematic review and meta-analysis. *World Psychiatry* 13:288-295, 2014
82. Wells A: *Metacognitive Therapy for Anxiety and Depression*. New York, NY, The Guilford Press, 2008
83. Hayes SC, Strosahl KD, Wilson KG: *Acceptance and Commitment Therapy: The Process and Practice of Mindful Change* (ed 2). New York, NY, The Guilford Press, 2012
84. Collins LM: *Optimization of Behavioral, Biobehavioral, and Biomedical Interventions. The Multiphase Optimization Strategy (MOST)*. Cham, Switzerland, Springer, 2018
85. Fisher AJ, Boswell JF: Enhancing the personalization of psychotherapy with dynamic assessment and modeling. *Assessment* 23:496-506, 2016



AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Effect of Psychological Intervention on Fear of Cancer Recurrence: A Systematic Review and Meta-Analysis

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ffc.

Andreas Dinkel

Honoraria: Novartis Pharma

Allan "Ben" Smith

Research Funding: AstraZeneca (Inst), Pfizer (Inst)

Belinda Thewes

Employment: The Health Psychology Clinic

Robert Zachariae

Stock and Other Ownership Interests: Novo Nordisk

Honoraria: Pfizer, Sanofi

Research Funding: Boehringer Ingelheim (Inst)

No other potential conflicts of interest were reported.